Vascular endothelial growth factor is essential for corpus luteum angiogenesis

被引:520
作者
Ferrara, N
Chen, H
Davis-Smyth, T
Gerber, HP
Nguyen, TN
Peers, D
Chisholm, V
Hillan, KJ
Schwall, RH
机构
[1] Genentech Inc, Dept Cardiovasc Res, S San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Proc Sci, S San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA
[4] Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA
关键词
D O I
10.1038/nm0398-336
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The development and endocrine function of the ovarian corpus luteum (CL) are dependent on the growth of new capillary vessels. Although several molecules have been implicated as mediators of CL angiogenesis, at present there is no direct evidence for the involvement of any. Here we report the unexpected finding that treatment with truncated soluble Flt-1 receptors, which inhibit vascular endothelial growth factor (VEGF) bioactivity, resulted in virtually complete suppression of CL angiogenesis in a rat model of hormonally induced ovulation. This effect was associated with inhibition of CL development and progesterone release. Failure of maturation of the endometrium was also observed. Areas of ischemic necrosis were demonstrated in the corpora lutea (CLs) of treated animals. However, no effect on the preexisting ovarian vasculature was observed. These findings demonstrate that, in spite of the redundancy of potential mediators, VEGF is essential for CL angiogenesis. Furthermore, they have implications for the control of fertility and the treatment of ovarian disorders characterized by hypervascularity and hyperplasia.
引用
收藏
页码:336 / 340
页数:5
相关论文
共 25 条
[1]
SUPPRESSION OF RETINAL NEOVASCULARIZATION IN-VIVO BY INHIBITION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR (VEGF) USING SOLUBLE VEGF-RECEPTOR CHIMERIC PROTEINS [J].
AIELLO, LP ;
PIERCE, EA ;
FOLEY, ED ;
TAKAGI, H ;
CHEN, H ;
RIDDLE, L ;
FERRARA, N ;
KING, GL ;
SMITH, LEH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (23) :10457-10461
[2]
The changes in the vascular pattern of the ovary of the albino rat during the estrous cycle [J].
Basset, DL .
AMERICAN JOURNAL OF ANATOMY, 1943, 73 (02) :251-291
[3]
Heterodimers of placenta growth factor vascular endothelial growth factor - Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR [J].
Cao, YH ;
Chen, H ;
Zhou, L ;
Chiang, MK ;
AnandApte, B ;
Weatherbee, JA ;
Wang, YD ;
Fang, FY ;
Flanagan, JG ;
Tsang, MLS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (06) :3154-3162
[4]
DESIGNING CD4 IMMUNOADHESINS FOR AIDS THERAPY [J].
CAPON, DJ ;
CHAMOW, SM ;
MORDENTI, J ;
MARSTERS, SA ;
GREGORY, T ;
MITSUYA, H ;
BYRN, RA ;
LUCAS, C ;
WURM, FM ;
GROOPMAN, JE ;
BRODER, S ;
SMITH, DH .
NATURE, 1989, 337 (6207) :525-531
[5]
CHISHOLM V, 1995, DNA CLONING, V4, P1
[6]
The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade [J].
DavisSmyth, T ;
Chen, H ;
Park, J ;
Presta, LG ;
Ferrara, N .
EMBO JOURNAL, 1996, 15 (18) :4919-4927
[7]
THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
DEVRIES, C ;
ESCOBEDO, JA ;
UENO, H ;
HOUCK, K ;
FERRARA, N ;
WILLIAMS, LT .
SCIENCE, 1992, 255 (5047) :989-991
[8]
OVARIAN HYPERSTIMULATION SYNDROME - REPORT OF A CASE WITH NOTES ON PATHOGENESIS AND TREATMENT [J].
ENGEL, T ;
SPEROFF, L ;
VANDEWIE.RL ;
JEWELEWICZ, R ;
DYRENFURTH, I .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1972, 112 (08) :1052-+
[9]
The biology of vascular endothelial growth factor [J].
Ferrara, N ;
DavisSmyth, T .
ENDOCRINE REVIEWS, 1997, 18 (01) :4-25
[10]
FINNERTY H, 1993, ONCOGENE, V8, P2293